N'-[5-(5-chloro-3-pyrimidin-5-yl-1H-pyrrolo[2,3-b]pyridin-2-yl)pyridin-2-yl]-N,N,N'-trimethylpropane-1,3-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: N'-[5-(5-chloro-3-pyrimidin-5-yl-1H-pyrrolo[2,3-b]pyridin-2-yl)pyridin-2-yl]-N,N,N'-trimethylpropane-1,3-diamine
• 化学式: C₂₂H₂₄ClN₇
• 分子量: 421.9
• InChiKey: RXHJADAZUDEUBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  73.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] SUBSTITUTED PYRROLOPYRIDINES<br/>[FR] PYRROLOPYRIDINES SUBSTITUES
  申请人：ASTRAZENECA AB

  公开号：WO2004016609A1

  公开（公告）日：2004-02-26

  There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk.

  提供了式(I)的新化合物，其中R1、R2和R3如规范中所定义，并且其药学上可接受的盐；以及它们的制备方法、含有它们的组合物以及它们在治疗中的用途。这些化合物是激酶Itk的抑制剂。
• Substituted pyrrolopyridines
  申请人：Nielsen Aadal Peter

  公开号：US20050261331A1

  公开（公告）日：2005-11-24

  There are provided novel compounds of formula (I) wherein R 1 , R 2 and R 3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk.

  提供了公式（I）的新化合物，其中R1、R2和R3如规范中定义，并且其药学上可接受的盐；以及它们的制备过程、含有它们的组合物和它们在治疗中的用途。这些化合物是Itk激酶的抑制剂。
• SUBSTITUTED PYRROLOPYRIDINES
  申请人：AstraZeneca AB

  公开号：EP1539757A1

  公开（公告）日：2005-06-15
• EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20200224161A1

  公开（公告）日：2020-07-16

  Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
• Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20200347350A1

  公开（公告）日：2020-11-05

  Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes (PBLs) and marrow infiltrating lymphocytes (MILs), from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and genetic modifications of expanded TILs, PBLs, and MILs to incorporate chimeric antigen receptors, genetically modified T-cell receptors, and other genetic modifications, and uses of such expanded and/or modified TILs, PBLs, and MILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.